[
  {
    "objectID": "quarto/main.html",
    "href": "quarto/main.html",
    "title": "The Financial Toxicity of Universal SGLT2i in HF",
    "section": "",
    "text": "— CONSORT FLOW DIAGRAM DATA (Person-Years) —\nSTEP 1: Total MEPS Population (2021-2023) | N = 69,686\nExclusion 1: No HF Diagnosis | n = 69,141\nSTEP 2: Heart Failure Diagnosis (CCSR: CIR019) | N = 545 (0.8%)\nExclusion 2: Pediatric &lt; 18 | n = 0 (0.0%)\nSTEP 3: Adult Population (Age &gt;= 18) | N = 545 (100.0%)\nExclusion 3: No GDMT Exclusion (Universal Sample Retained) | n = 0\nSTEP 4: Broad HF Cohort | N = 545 (100.0%)\nExclusion 4: Uninsured/Other | n = 12 (2.2%)\nSTEP 5: Final Analytic Cohort (Valid Insurance) | N = 533 (97.8%)\n\n\n\n\n\n\n\nTable 1. Demographic and Clinical Characteristics of US Adults With Heart Failure by Insurance Type, 2021-2023.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 1,833,138 (100%)1\nMedicaid or Dual Eligible N = 582,020 (32%)1\nMedicare N = 1,083,339 (59%)1\nPrivate/Commercial N = 167,779 (9.2%)1\n\n\n\n\nCurrent SGLT2 Inhibitor Use\n242,314 (13%)\n72,502 (12%)\n137,103 (13%)\n32,709 (19%)\n\n\nAge Category\n\n\n\n\n\n\n\n\n\n\n    18-64 Years\n610,131 (33%)\n367,772 (63%)\n74,580 (6.9%)\n167,779 (100%)\n\n\n    65-74 Years\n421,899 (23%)\n117,246 (20%)\n304,653 (28%)\n0 (0%)\n\n\n    ≥75 Years\n801,109 (44%)\n97,003 (17%)\n704,106 (65%)\n0 (0%)\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n    Male\n840,041 (46%)\n222,755 (38%)\n506,953 (47%)\n110,333 (66%)\n\n\n    Female\n993,097 (54%)\n359,266 (62%)\n576,386 (53%)\n57,446 (34%)\n\n\nRace and Ethnicity\n\n\n\n\n\n\n\n\n\n\n    White\n1,336,511 (73%)\n353,994 (61%)\n892,945 (82%)\n89,572 (53%)\n\n\n    Black\n310,743 (17%)\n132,585 (23%)\n120,688 (11%)\n57,469 (34%)\n\n\n    Hispanic or Latino\n90,137 (4.9%)\n49,229 (8.5%)\n40,909 (3.8%)\n0 (0%)\n\n\n    Other Race and Ethnicity\n95,747 (5.2%)\n46,213 (7.9%)\n28,797 (2.7%)\n20,738 (12%)\n\n\nAnnual Household Income\n\n\n\n\n\n\n\n\n\n\n    Low (&lt;125% FPL)\n780,289 (43%)\n396,151 (68%)\n358,899 (33%)\n25,239 (15%)\n\n\n    Middle (125%-400% FPL)\n541,851 (30%)\n120,024 (21%)\n351,918 (32%)\n69,908 (42%)\n\n\n    High (&gt;400% FPL)\n510,999 (28%)\n65,845 (11%)\n372,522 (34%)\n72,632 (43%)\n\n\nEmployment Status\n\n\n\n\n\n\n\n\n\n\n    Not Employed\n1,326,914 (79%)\n493,390 (87%)\n810,986 (86%)\n22,538 (13%)\n\n\n    Employed\n351,772 (21%)\n74,051 (13%)\n132,479 (14%)\n145,241 (87%)\n\n\n\n1 n (%)\n\n\nNotes: Data derived from the Medical Expenditure Panel Survey (MEPS), pooled 2021–2023. Values represent weighted national estimates. SGLT2 indicates sodium-glucose cotransporter 2. Income categories are based on the Federal Poverty Level (FPL).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 2. Mean Annual Out-of-Pocket Health Care Expenditures Among US Adults With Heart Failure by Service Category and Demographic Subgroup.\n\n\n\n\n\n\n\n\n\n\nTotal Out-of-Pocket Expenditures\nPrescription Drugs\nHealth Insurance Premiums\nOutpatient and Office-Based Care\nInpatient Hospital Care\nOther Medical\n\n\n\n\nOverall Population\n\n\nOverall\n$3256 (2558-4143)\n$559 (396-789)\n$888 (610-1292)\n$458 (287-730)\n$205 (110-380)\n$1147 (682-1929)\n\n\nInsurance Type\n\n\nMedicaid or Dual Eligible\n$886 (521-1507)\n$102 (70-148)\n$322 (88-1172)\n$127 (48-337)\n$86 (28-264)\n$250 (115-544)\n\n\nMedicare\n$4108 (3146-5365)\n$834 (574-1211)\n$826 (526-1296)\n$531 (295-955)\n$173 (75-399)\n$1744 (994-3060)\n\n\nPrivate/Commercial\n$5971 (3408-10461)\n$373 (239-582)\n$3248 (1713-6159)\n$1129 (518-2462)\n$820 (244-2751)\n$401 (201-798)\n\n\nAge Group\n\n\n18-64 Years\n$2307 (1410-3774)\n$210 (151-291)\n$1112 (574-2154)\n$417 (197-882)\n$307 (123-769)\n$262 (131-520)\n\n\n65-74 Years\n$3431 (2267-5194)\n$765 (479-1221)\n$980 (443-2169)\n$428 (145-1265)\n$106 (49-229)\n$1152 (649-2045)\n\n\n≥75 Years\n$3886 (2674-5645)\n$717 (411-1251)\n$668 (421-1060)\n$504 (251-1012)\n$178 (61-519)\n$1818 (888-3724)\n\n\nSex\n\n\nMale\n$3097 (2262-4240)\n$657 (368-1172)\n$948 (622-1445)\n$332 (180-614)\n$144 (100-207)\n$1016 (495-2085)\n\n\nFemale\n$3390 (2306-4983)\n$477 (335-677)\n$836 (443-1577)\n$564 (304-1044)\n$256 (104-631)\n$1257 (593-2666)\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n$1814 (1331-2473)\n$428 (277-662)\n$485 (242-972)\n$303 (144-639)\n$133 (69-259)\n$464 (306-704)\n\n\nMiddle (125%-400% FPL)\n$3684 (2236-6069)\n$607 (339-1086)\n$798 (495-1285)\n$412 (207-821)\n$161 (67-387)\n$1706 (637-4569)\n\n\nHigh (&gt;400% FPL)\n$5003 (3441-7274)\n$708 (435-1152)\n$1598 (868-2940)\n$742 (352-1565)\n$359 (114-1135)\n$1595 (751-3390)\n\n\nRace and Ethnicity\n\n\nWhite\n$3396 (2556-4510)\n$498 (399-621)\n$787 (528-1175)\n$496 (298-828)\n$205 (108-389)\n$1409 (791-2509)\n\n\nBlack\n$3148 (1507-6573)\n$848 (270-2663)\n$1370 (522-3596)\n$237 (72-779)\n$252 (36-1739)\n$441 (124-1569)\n\n\nHispanic or Latino\n$3145 (755-13100)\n$775 (121-4950)\n$782 (115-5329)\n$926 (93-9199)\n$112 (20-619)\n$550 (86-3540)\n\n\nOther Race and Ethnicity\n$1757 (1080-2858)\n$274 (129-581)\n$820 (376-1787)\n$190 (33-1083)\n$138 (29-658)\n$335 (96-1168)\n\n\n\nNotes: Values represent mean annual out-of-pocket (OOP) expenditures. All costs are adjusted to 2023 US dollars. Confidence intervals (95%) were calculated using bootstrap-estimated standard errors (2000 replicates) and log-transformation to account for the right-skewed distribution of health care costs.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 3. Projected Incidence of Financial Toxicity Among Medicare Beneficiaries Under Universal SGLT2 Inhibitor Adherence and Inflation Reduction Act Scenarios.\n\n\n\n\n\n\n\n\n\n\nBaseline Utilization, % (95% CI)\nBaseline Median Burden\nUniversal SGLT2 Inhibitor Adherence, % (95% CI)\nUniversal Median Burden\nInflation Reduction Act Implementation, % (95% CI)\nPost-IRA Median Burden\nAbsolute Risk Reduction, %\nRelative Risk Reduction, %\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n30.6 (23.2-39.0)\n5.8%\n35.3 (27.5-43.9)\n8.6%\n33.7 (25.8-42.5)\n7.9%\n1.6\n4.6\n\n\nAge Group\n\n\n18-64 Years\n26.6 (--)\n7.4%\n42.4 (--)\n10.1%\n42.4 (--)\n10.1%\n0.0\n0.0\n\n\n65-74 Years\n27.6 (17.3-41.1)\n5.8%\n32.0 (21.4-44.7)\n7.5%\n31.4 (20.8-44.4)\n7.5%\n0.6\n1.7\n\n\n≥75 Years\n32.2 (22.9-43.2)\n5.8%\n36.0 (26.2-47.0)\n8.0%\n33.7 (24.1-44.9)\n7.7%\n2.3\n6.3\n\n\nSex\n\n\nMale\n25.9 (17.4-36.6)\n5.7%\n32.8 (22.5-45.0)\n8.4%\n30.0 (19.8-42.7)\n7.7%\n2.8\n8.4\n\n\nFemale\n34.7 (24.4-46.6)\n5.8%\n37.5 (27.3-48.8)\n8.7%\n36.8 (26.7-48.2)\n8.0%\n0.7\n1.7\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n64.9 (45.7-80.2)\n19.6%\n76.7 (55.2-89.8)\n27.5%\n76.2 (55.0-89.4)\n25.1%\n0.5\n0.6\n\n\nMiddle (125%-400% FPL)\n23.4 (12.1-40.5)\n9.0%\n25.9 (14.6-41.6)\n10.7%\n22.4 (12.5-36.7)\n10.6%\n3.5\n13.5\n\n\nHigh (&gt;400% FPL)\n4.3 (0.2-53.4)\n2.1%\n4.3 (0.2-53.4)\n2.9%\n3.3 (--)\n2.9%\n1.0\n23.6\n\n\nRace and Ethnicity\n\n\nWhite\n26.9 (19.0-36.6)\n5.6%\n32.6 (23.9-42.5)\n7.9%\n31.9 (23.4-41.9)\n7.7%\n0.6\n1.9\n\n\nBlack\n49.7 (29.7-69.9)\n10.6%\n50.5 (30.4-70.5)\n12.5%\n40.3 (18.1-67.5)\n11.8%\n10.2\n20.1\n\n\nHispanic or Latino\n43.4 (--)\n5.4%\n43.4 (--)\n5.9%\n43.4 (--)\n5.9%\n0.0\n0.0\n\n\nOther Race and Ethnicity\n44.7 (--)\n12.3%\n44.7 (--)\n15.6%\n44.7 (--)\n15.6%\n0.0\n0.0\n\n\n\nNotes: Financial toxicity is defined as annual out-of-pocket health care expenditures (including premiums) exceeding 20% of post-subsistence income (income remaining after food, clothing, transportation, shelter, and other necessities). ‘Universal SGLT2 Inhibitor Adherence’ assumes 100% adherence to guideline-directed therapy. ‘Inflation Reduction Act Implementation’ applies a $2,000 annual pharmacy cap to the Medicare Part D portion. CIs calculated using Logit-transformed intervals based on bootstrap standard errors (2000 replicates). ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 4. Policy Efficiency Metrics Among Medicare Beneficiaries: Number Needed to Treat/Harm and Projected Cases of Financial Toxicity Prevented.\n\n\n\n\n\n\n\n\n\n\nEconomic Number Needed to Harm\nEconomic Number Needed to Treat\nProjected Cases Prevented, No.\n\n\n\n\nOverall\n\n\nOverall\n21\n61\n17,692\n\n\nAge Group\n\n\n18-64 Years\n6\nNegl.\n0\n\n\n65-74 Years\n23\n180\n1,693\n\n\n≥75 Years\n27\n44\n15,999\n\n\nSex\n\n\nMale\n14\n36\n13,943\n\n\nFemale\n36\n154\n3,749\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n8\nNegl.\n1,693\n\n\nMiddle (125%-400% FPL)\n40\n29\n12,250\n\n\nHigh (&gt;400% FPL)\nNegl.\n99\n3,749\n\n\nRace and Ethnicity\n\n\nWhite\n18\n164\n5,442\n\n\nBlack\n132\n10\n12,250\n\n\nHispanic or Latino\nNegl.\nNegl.\n0\n\n\nOther Race and Ethnicity\nNegl.\nNegl.\n0\n\n\n\nNotes: Economic Number Needed to Harm indicates the number of patients prescribed Universal SGLT2 inhibitors to cause one new case of financial toxicity. Economic Number Needed to Treat indicates the number of patients benefiting from the IRA cap to prevent one case of financial toxicity. ‘Negl.’ = Negligible risk difference (&lt;0.5%).\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 1. Prevalence of Financial Toxicity and Composition of Out-of-Pocket Costs Among Medicare Beneficiaries by Policy Scenario.\n\n\n\n\n\n\n\n\n\n\nFigure 2. Changes in Financial Toxicity Prevalence Among Medicare Beneficiaries Under the Inflation Reduction Act by Demographic Subgroup.\n\n\n\n\n\n\n\n\n\n\nFigure 3. Distribution of Insurance Coverage Types Among US Adults With Heart Failure Across Racial and Economic Subgroups.\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 1. Median Annual Out-of-Pocket Costs for SGLT2 Inhibitors by Insurance Type.\n\n\n\n\n\n\n\n\n\nInsurance Plan\nAnnual SGLT2i Cost (IQR)\n\n\n\n\nMedicaid or Dual Eligible\n$0 ($0-$0)\n\n\nMedicare\n$532 ($46-$1337)\n\n\nPrivate/Commercial\n$91 ($91-$91)\n\n\n\nNotes: Values are Median (Interquartile Range [Q1-Q3]). Costs are adjusted to 2023 dollars. Calculated using weighted survey quantiles.\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 2. Projected Annual Out-of-Pocket Savings for Medicare Beneficiaries Stratified by Demographic Subgroups with 95% Bootstrap CIs.\n\n\n\n\n\n\n\n\n\n\nPre-IRA OOP\nPost-IRA OOP\nNet Savings\n% Benefiting\nSavings (Beneficiaries)\n\n\n\n\nOverall Population\n\n\nOverall\n$4615 (3640-5852)\n$4330 (3377-5552)\n$285 (118-687)\n13.1 (7.9-20.8)\n$2179 (1209-3928)\n\n\nAge Group\n\n\n18-64 Years\n$1721 (1109-2670)\n$1716 (1106-2663)\n$5 (0-149)\n4.3 (--)\n$119 (--)\n\n\n65-74 Years\n$4950 (3488-7026)\n$4629 (3288-6516)\n$322 (109-953)\n15.4 (8.5-26.2)\n$2090 (824-5302)\n\n\n≥75 Years\n$4777 (3394-6723)\n$4478 (3141-6385)\n$299 (88-1016)\n13.0 (6.5-24.3)\n$2297 (987-5344)\n\n\nSex\n\n\nMale\n$4148 (2916-5899)\n$3752 (2644-5324)\n$396 (111-1413)\n13.2 (5.2-29.7)\n$2999 (1294-6951)\n\n\nFemale\n$5026 (3462-7297)\n$4839 (3303-7090)\n$187 (72-487)\n13.0 (8.1-20.2)\n$1445 (665-3139)\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n$3213 (2287-4514)\n$2921 (2175-3924)\n$292 (98-864)\n12.2 (6.5-21.7)\n$2391 (1035-5523)\n\n\nMiddle (125%-400% FPL)\n$5203 (3117-8685)\n$4924 (2868-8456)\n$278 (58-1331)\n13.9 (6.5-27.3)\n$1998 (550-7257)\n\n\nHigh (&gt;400% FPL)\n$5411 (3758-7791)\n$5127 (3526-7455)\n$284 (83-980)\n13.1 (4.8-31.2)\n$2170 (864-5449)\n\n\nRace and Ethnicity\n\n\nWhite\n$4582 (3445-6093)\n$4456 (3335-5952)\n$126 (55-289)\n11.1 (6.8-17.7)\n$1135 (611-2106)\n\n\nBlack\n$4498 (2343-8635)\n$3173 (1466-6865)\n$1326 (339-5187)\n30.6 (6.9-72.6)\n$4328 (1821-10288)\n\n\nHispanic or Latino\n$6999 (1983-24705)\n$6114 (2098-17817)\n$884 (53-14810)\n13.6 (--)\n$6506 (--)\n\n\nOther Race and Ethnicity\n$2762 (1134-6732)\n$2762 (1134-6732)\n$0 (--)\n0.0 (--)\n--\n\n\n\nNotes: Estimates apply specifically to the Medicare beneficiary population. Values are Mean (95% CI). Costs are adjusted to 2023 dollars. CIs calculated using bootstrap standard errors with log-transformation for costs and logit-transformation for proportions. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 3. Sensitivity Analysis: Projected Financial Toxicity (FT) in All US Adults With Heart Failure (Including Non-Medicare Populations). Note: Impact is diluted as ~40% of the population (Commercial/Medicaid) is ineligible for the IRA cap.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nBaseline Median Burden\nUniversal SGLT2i (95% CI)\nUniversal Median Burden\nPost-IRA (95% CI)\nPost-IRA Median Burden\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Patients\n32.5 (26.0-39.7)\n3.9%\n35.3 (28.5-42.7)\n5.5%\n34.3 (27.6-41.7)\n5.3%\n1.0\n2.7\n\n\nAge Group\n\n\n18-64 Years\n32.8 (22.6-44.9)\n2.4%\n34.7 (24.0-47.2)\n2.4%\n34.7 (24.0-47.2)\n2.4%\n0.0\n0.0\n\n\n65-74 Years\n29.3 (19.0-42.4)\n5.4%\n32.4 (21.8-45.3)\n5.7%\n32.0 (21.4-45.0)\n5.7%\n0.4\n1.2\n\n\n≥75 Years\n33.9 (25.3-43.8)\n4.6%\n37.2 (28.2-47.2)\n7.7%\n35.2 (26.3-45.3)\n6.7%\n2.0\n5.4\n\n\nSex\n\n\nMale\n26.5 (18.7-36.2)\n3.4%\n30.7 (21.7-41.5)\n4.5%\n29.1 (20.1-40.0)\n4.4%\n1.7\n5.4\n\n\nFemale\n37.5 (29.4-46.4)\n4.2%\n39.1 (31.1-47.8)\n6.1%\n38.8 (30.7-47.4)\n6.1%\n0.4\n1.0\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n61.6 (50.0-72.0)\n11.9%\n67.1 (55.2-77.1)\n20.2%\n66.8 (55.1-76.8)\n20.2%\n0.2\n0.3\n\n\nMiddle (125%-400% FPL)\n15.8 (8.3-28.2)\n5.7%\n17.5 (9.9-28.9)\n6.9%\n15.2 (8.6-25.4)\n6.7%\n2.3\n13.0\n\n\nHigh (&gt;400% FPL)\n5.6 (1.4-19.6)\n2.0%\n5.6 (1.4-19.6)\n2.3%\n4.9 (1.0-21.1)\n2.3%\n0.7\n13.0\n\n\nRace and Ethnicity\n\n\nWhite\n27.7 (20.4-36.4)\n3.9%\n31.4 (23.8-40.3)\n5.6%\n31.0 (23.4-39.9)\n5.5%\n0.4\n1.3\n\n\nBlack\n47.5 (31.9-63.5)\n5.4%\n47.8 (32.2-63.8)\n5.5%\n43.8 (27.6-61.5)\n4.4%\n3.9\n8.3\n\n\nHispanic or Latino\n44.0 (--)\n2.4%\n44.0 (--)\n2.4%\n44.0 (--)\n2.4%\n0.0\n0.0\n\n\nOther Race and Ethnicity\n40.0 (--)\n6.8%\n40.0 (--)\n6.9%\n40.0 (--)\n6.9%\n0.0\n0.0\n\n\nInsurance Type\n\n\nMedicaid or Dual Eligible\n40.2 (29.2-52.3)\n0.8%\n40.2 (29.2-52.3)\n0.8%\n40.2 (29.2-52.3)\n0.8%\n0.0\n0.0\n\n\nMedicare\n30.6 (23.2-39.0)\n5.8%\n35.3 (27.5-43.9)\n8.6%\n33.7 (25.8-42.5)\n7.9%\n1.6\n4.6\n\n\nPrivate/Commercial\n18.1 (5.5-45.7)\n6.8%\n18.1 (5.5-45.7)\n6.9%\n18.1 (5.5-45.7)\n6.9%\n0.0\n0.0\n\n\n\nNotes: CIs calculated using Logit-transformed intervals based on bootstrap standard errors (2000 replicates). ‘Median Burden’ represents the median percentage of post-subsistence income spent on healthcare. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 4. Projected Incidence of Catastrophic Financial Toxicity (&gt;40% of Income) Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n22.0 (15.6-30.1)\n22.4 (15.8-30.6)\n20.7 (14.3-29.1)\n1.7\n7.4\n\n\nAge Group\n\n\n18-64 Years\n23.9 (--)\n23.9 (--)\n23.9 (--)\n0.0\n0.0\n\n\n65-74 Years\n18.9 (9.6-33.7)\n18.9 (9.6-33.7)\n18.1 (8.9-33.4)\n0.8\n4.1\n\n\n≥75 Years\n23.1 (15.4-33.3)\n23.7 (15.7-34.1)\n21.5 (13.9-31.8)\n2.2\n9.3\n\n\nSex\n\n\nMale\n20.3 (12.5-31.1)\n21.1 (13.2-32.0)\n17.8 (10.5-28.8)\n3.3\n15.4\n\n\nFemale\n23.5 (14.8-35.2)\n23.5 (14.8-35.2)\n23.2 (14.5-35.1)\n0.2\n1.0\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n56.3 (39.1-72.2)\n56.3 (39.1-72.2)\n54.8 (37.6-70.8)\n1.6\n2.8\n\n\nMiddle (125%-400% FPL)\n10.2 (0.3-82.5)\n11.4 (1.2-58.1)\n7.9 (0.3-72.7)\n3.5\n30.6\n\n\nHigh (&gt;400% FPL)\n0.0 (--)\n0.0 (--)\n0.0 (--)\n0.0\n–\n\n\nRace and Ethnicity\n\n\nWhite\n17.2 (11.0-25.9)\n17.6 (11.3-26.5)\n17.5 (11.2-26.3)\n0.2\n0.9\n\n\nBlack\n48.6 (28.7-68.9)\n48.6 (28.7-68.9)\n34.9 (15.0-62.0)\n13.7\n28.1\n\n\nHispanic or Latino\n32.7 (--)\n32.7 (--)\n32.7 (--)\n0.0\n0.0\n\n\nOther Race and Ethnicity\n44.7 (--)\n44.7 (--)\n44.7 (--)\n0.0\n0.0\n\n\n\nNotes: Catastrophic toxicity defined as annual person-level out-of-pocket health care expenditures (including premiums) exceeding 40% of post-subsistence family income. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Figure 1. Reductions in Catastrophic Financial Toxicity (&gt;40%) Among Medicare Beneficiaries by Demographic Subgroup."
  }
]